Clinical lung cancer最新文献

{"title":"Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC.","authors":"Alessandro Leonetti, Veronica Cervati, Roberta Minari, Maura Scarlattei, Michela Verzè, Marianna Peroni, Monica Pluchino, Francesco Bonatti, Fabiana Perrone, Giulia Mazzaschi, Agnese Cosenza, Letizia Gnetti, Paola Bordi, Livia Ruffini, Marcello Tiseo","doi":"10.1016/j.cllc.2024.07.016","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.07.016","url":null,"abstract":"<p><strong>Objectives: </strong>Despite the outstanding results achieved by osimertinib for the treatment of advanced EGFR-mutated NSCLC, the development of resistance is almost inevitable. While molecular mechanism responsible for osimertinib resistance are being mostly revealed, the definition of predictive biomarkers is crucial in order to identify patients at higher risk of progression and optimize treatment strategy.</p><p><strong>Materials and methods: </strong>This is a prospective single-center study aimed to assess the potential role of liquid biopsy and 18F-FDG PET/CT derived metabolic parameters as noninvasive predictive biomarkers of osimertinib outcomes in advanced EGFR-mutated NSCLC patients. Patients underwent blood samples for ctDNA analysis at baseline, after 15 days and 1 month (t1) of osimertinib. 18F-FDG PET/CT was performed at baseline and after 1 month of osimertinib.</p><p><strong>Results: </strong>Seventy-two advanced EGFR-mutated NSCLC patients treated with osimertinib in first (n = 63) and in second-line (n = 9) were prospectively enrolled. Baseline positive shedding status was significantly associated with a shorter progression-free survival (PFS) (9.5 vs. 29.2 months, P = .031). Early metabolic response (MR) led to improved PFS (16.8 vs. 5.5 months, P = .038) and OS (35.2 vs. 15.3 months, P = .047). Early MR was significantly correlated with subsequent radiologic response (P = .010). All 18F-FDG PET/CT baseline parameters were significantly related to baseline EGFR activating mutation allele frequency. Both clearance and no detection of EGFR at t1 were significantly associated with MR (P = .001 and P = .004, respectively).</p><p><strong>Conclusion: </strong>Molecular and 18F-FDG PET/CT derived metabolic parameters might represent a useful tool to predict osimertinib outcome in advanced EGFR-mutated NSCLC patients.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142092493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis","authors":"Felipe Soto-Lanza ,&nbsp;Lydia Glick ,&nbsp;Colin Chan ,&nbsp;Linda Zhong ,&nbsp;Nathaniel Wilson ,&nbsp;Saadia Faiz ,&nbsp;Saumil Gandhi ,&nbsp;Aung Naing ,&nbsp;John V. Heymach ,&nbsp;Vickie R. Shannon ,&nbsp;Maria Franco-Vega ,&nbsp;Zhongxing Liao ,&nbsp;Steven H. Lin ,&nbsp;Nicolas L. Palaskas ,&nbsp;Jia Wu ,&nbsp;Girish S. Shroff ,&nbsp;Mehmet Altan ,&nbsp;Ajay Sheshadri","doi":"10.1016/j.cllc.2024.07.017","DOIUrl":"10.1016/j.cllc.2024.07.017","url":null,"abstract":"<div><h3>Aims</h3><div>Despite known short-term mortality risk of immune checkpoint inhibitor (ICI) pneumonitis, its impact on 1-year mortality, long-term pulmonary function, symptom persistence, and radiological resolution remains unclear.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 71 nonsmall cell lung cancer (NSCLC) patients treated with anti-PD(L)1 monoclonal antibodies between 2018-2021, who developed pneumonitis. Clinical and demographic covariates were collected from electronic medical record. Cox regression assessed associations with mortality, while logistic regression evaluated associations with persistent symptoms, hypoxemia, and radiological resolution.</div></div><div><h3>Results</h3><div>Steroid-refractory pneumonitis (hazard ratio [HR] = 15.1, 95% confidence interval [95% CI]:3.9-57.8, <em>P</em> &lt; .0001) was associated with higher 1-year mortality compared to steroid-responsive cases. However, steroid-resistant (odds ratio [OR] = 1.4, 95% CI: 0.4-5.1, <em>P</em> = .58) and steroid-dependent (OR = 0.4, 95% CI: 0.1-1.2, <em>P</em> = .08) pneumonitis were not. Nonadenocarcinoma histology (OR = 6.7, 95% CI: 1.6-46.6, <em>P</em> = .01), grade 3+ pneumonitis (OR = 4.6, 95% CI: 1.3-22.7, <em>P</em> = .03), and partial radiological resolution (OR = 6.3, 95% CI: 1.8-23.8, <em>P</em> = .004) were linked to increased pulmonary symptoms after pneumonitis resolution. Grade 3+ pneumonitis (OR = 8.1, 95% CI: 2.3-31.5, <em>P</em> = .001) and partial radiological resolution (OR = 5.45, 95% CI: 1.29-37.7, <em>P</em> = .03) associated with residual hypoxemia. Nonadenocarcinoma histology (OR = 3.6, 95% CI: 1.01-17.6, <em>P</em> = .06) and pretreatment ILAs (OR = 4.8, 95% CI: 1.14-33.09, <em>P</em> = .05) were associated with partial radiological resolution.</div></div><div><h3>Conclusions</h3><div>Steroid refractory pneumonitis increases 1-year mortality in NSCLC patients. Pretreatment ILAs may signal predisposition to fibrosis-related outcomes, seen as partial resolution, which in turn is associated with postresolution symptoms and residual hypoxemia. These findings offer insights for identifying patients at risk of adverse outcomes post-pneumonitis resolution.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)","authors":"Hayato Kawachi ,&nbsp;Motohiro Tamiya ,&nbsp;Yuko Oya ,&nbsp;Go Saito ,&nbsp;Yoshihiko Taniguchi ,&nbsp;Hirotaka Matsumoto ,&nbsp;Yuki Sato ,&nbsp;Taiichiro Otsuki ,&nbsp;Hidekazu Suzuki ,&nbsp;Yasushi Fukuda ,&nbsp;Satoshi Tanaka ,&nbsp;Yoko Tsukita ,&nbsp;Junji Uchida ,&nbsp;Yoshihiko Sakata ,&nbsp;Yuki Nakatani ,&nbsp;Ryota Shibaki ,&nbsp;Daisuke Arai ,&nbsp;Asuka Okada ,&nbsp;Satoshi Hara ,&nbsp;Koichi Takayama ,&nbsp;Kazumi Nishino","doi":"10.1016/j.cllc.2024.07.014","DOIUrl":"10.1016/j.cllc.2024.07.014","url":null,"abstract":"<div><h3>Background</h3><div>The optimal subsequent treatment strategy for locally advanced non-small cell lung cancer (LA-NSCLC) after chemoradiotherapy (CRT) and consolidative durvalumab therapy remains unknown. We aimed to determine the optimal subsequent treatment strategy for this clinical population.</div></div><div><h3>Materials and Methods</h3><div>We retrospectively enrolled 523 consecutive patients with LA-NSCLC treated with CRT and analyzed the treatment outcomes of subsequent therapy after progression following CRT and consolidative durvalumab therapy. Patients who received tyrosine kinase inhibitors as subsequent therapy were excluded.</div></div><div><h3>Results</h3><div>Out of 122 patients who received subsequent chemotherapy, 55% underwent platinum-based, 25% non-platinum-based, and 20% immune checkpoint inhibitor (ICI)-containing therapies. In the platinum-based group, patients with a durvalumab-progression-free survival (Dur-PFS) ≥ 1 year had a significantly longer median subsequent therapy-PFS (SubTx-PFS) than those with Dur-PFS &lt; 1 year (13.2 months vs. 4.7 months; hazard ratio, 0.45; 95% confidence interval, 0.21–0.97; <em>P</em> = .04). Furthermore, among patients receiving non-platinum-based chemotherapy, the median SubTx-PFS was longer in the combined with angiogenesis inhibitor group than in the without group, although the difference was not statistically significant. No significant difference of SubTx-PFS was observed between the reason for durvalumab discontinuation and the outcomes of ICI-containing therapy.</div></div><div><h3>Conclusion</h3><div>In clinical practice, platinum-based chemotherapy rechallenge is frequently employed following progression subsequent to CRT and consolidative durvalumab therapy for LA-NSCLC. Optimal treatment strategies may consider Dur-PFS and angiogenesis inhibitor feasibility. Further research is warranted to identify clinical biomarkers that can help identify patients who would benefit from ICI rechallenge.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141848899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RBM10 mutation as a potential negative prognostic/predictive biomarker to therapy in non-small-cell lung cancer","authors":"Amanda Reyes, Michelle Afkhami, Erminia Massarelli, Jeremy Fricke, Isa Mambetsariev, Xiaochen Li, Giovanny Velasquez, Ravi Salgia","doi":"10.1016/j.cllc.2024.07.010","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.07.010","url":null,"abstract":"According to WHO, lung cancer is the leading cause of cancer-related death worldwide, but treatment has advanced in the last decade. The widespread use of Next Generation Sequencing has led to the discovery of several pathogenic mutations including RNA binding motif 10 [RBM10], a part of the spliceosome complex that regulates splicing of pre-mRNA. Electronic medical records were utilized to create a database of patients [50 patients] seen from 2018-2023 with NSCLC and mutations, with appropriate IRB approval. For sub-group analysis, we separated into groups by rapid progression vs stable disease defined as progression-free survival earlier than respective clinical trials. From the analysis of treatment response the mutated population had a median PFS was 6.7 months compared to 13.9 in the wild-type RBM10 population controlled for driver mutations TP53 mutation had a higher representation in the RBM10 mutated rapid progression group than the stable disease group. The ZFHX3 mutation had a higher representation in the RBM10 mutated stable disease group. mutations were associated with aggressive disease with treatment progression faster than median durations of response. mutations with concurrent ZFHX3 and EGFR mutations were associated with more stable disease, while concurrent KRAS and TP53 predicted even more aggressive disease. The widespread use of Next Generation Sequencing has led to the discovery of several pathogenic mutations including RBM10. From a database of patients with NSCLC, mutations were associated with aggressive disease with treatment progression faster than median durations of response. mutations with concurrent ZFHX3 and EGFR mutations were associated with more stable disease, while concurrent KRAS and TP53 predicted even more aggressive disease.","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141785170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients with Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy after EGFR Inhibition","authors":"Fabian Acker, Alexandra Klein, Anna Rasokat, Anna Eisert, Anna Kron, Petros Christopoulos, Albrecht Stenzinger, Jonas Kulhavy, Horst-Dieter Hummel, Cornelius Waller, Anne Hummel, Achim Rittmeyer, Cornelia Kropf-Sanchen, Heiner Zimmermann, Alisa Lörsch, Diego Kauffmann-Guerrero, Maret Schütz, Franziska Herster, Franziska Thielert, Melanie Demes, Friederike C. Althoff, Lukas Aguinarte, Sophie Heinzen, Maximilian Rost, Hanna Schulte, Jan Stratmann, Gernot Rohde, Reinhard Büttner, Jürgen Wolf, Martin Sebastian, Sebastian Michels, national Network Genomic Medicine Lung Cancer","doi":"10.1016/j.cllc.2024.07.012","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.07.012","url":null,"abstract":"MET amplification is a common resistance mechanism to EGFR inhibition in EGFR-mutant non-small cell lung cancer (NSCLC). Several trials showed encouraging results with combined EGFR and MET inhibition (EGFRi/METi). However, MET amplification has been inconsistently defined and frequently included both polysomy and true amplification. This is a multicenter, real-world analysis in patients with disease progression on EGFR inhibition and MET copy number gain (CNG), defined as either true amplification (MET to centromere of chromosome 7 ratio [MET-CEP7] ≥2) or polysomy (gene copy number ≥5, MET-CEP7 <2). A total of 43 patients with MET CNG were included, 42 of whom were detected by FISH. Twenty-three, 7, and 14 received EGFRi/METi, METi, and SoC, respectively. Patients in the EGFRi/METi cohort exhibited a superior real-world clinical benefit rate, defined as stable disease or better, of 82% (95% confidence interval [CI], 60-95) compared to METi (29%, 4-71) and SoC (50%, 23-77). Median real-world progression-free survival was longer with EGFRi/METi with 9.8 vs. 4.3 months with METi (hazard ratio [HR], 0.19, 95% CI, 0.06-0.57) and 3.7 months with SoC (0.41, 0.18-0.91), respectively. Overall survival was numerically improved. Interaction analysis with treatment and type of CNG (amplification vs. polysomy) suggests that differences were exclusively driven by MET-amplified patients receiving EGFRi/METi (HR for OS, 0.09, 0.01-0.54). In this real-world study, EGFRi/METi showed clinical benefit over METi and SoC. Future studies should focus on the differential impact of the type of MET CNG with a focus on true MET amplification as predictor of response. : MET amplification is a common resistance mechanism to EGFR inhibition in NSCLC. However, the term MET amplification has been used inconsistently and frequently included polysomy. In this retrospective study, patients with true MET amplification rather than polysomy derived clinical benefit from combined MET and EGFR inhibition compared to SoC.","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141785169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical exercise during neoadjuvant treatments for non-small cell lung cancer: the time is coming","authors":"Alice Avancini, Diana Giannarielli, Lorenzo Belluomini, Federico Schena, Michele Milella, Sara Pilotto","doi":"10.1016/j.cllc.2024.07.015","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.07.015","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141771625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer Patients","authors":"Prerana Jha, Asim Joshi, Rohit Mishra, Ranendra Pratap Biswal, Pooja Mahesh Kulkarni, Sewanti Limaye, Govind Babu, Ullas Batra, Prabhat Malik, Rajiv Kumar, Minit Shah, Nandini Menon, Amit Rauthan, Moni Kuriakose, Venkataramanan Ramachandran, Vanita Noronha, Prashant Kumar, Kumar Prabhash","doi":"10.1016/j.cllc.2024.07.011","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.07.011","url":null,"abstract":"The genomic landscape of non-small cell lung cancer (NSCLC) in the Indian patients remains underexplored. We revealed distinctive genomic alterations of Indian NSCLC patients, thereby providing vital molecular insights for implementation of precision therapies. We analyzed the genomic profiles of 325 lung adenocarcinoma and 81 lung squamous carcinoma samples from Indian patients using targeted sequencing of 50 cancer related genes. Correlations between genomic alterations and clinical characteristics were computed using statistical analyses. Additionally, we identified distinct features of Indian NSCLC genomes by comparison across different ethnicities. Our genomic analysis revealed several noticeable features of Indian NSCLC patients. Alterations in (45.8%), (27.4%), (11.4%) and (10.2%) were predominant in adenocarcinoma, with 68% eligible for targeted therapies. Squamous carcinoma exhibited prevalent alterations in (40.7%), (17.3%), and (8.6%). We observed higher frequency of alterations (18.5%) in lung squamous carcinoma patients, significantly distinct from other ethnicities reported till date. Beyond established correlations, we observed 60% of PD-L1 negative squamous patients harbored TP53 alterations, suggesting intriguing therapeutic implications. Our data revealed unique genomic variations of adenocarcinoma and squamous carcinoma patients, with significant indications for precision medicine and clinical practice of lung cancers. The study emphasizes the importance of clinical utility of NGS for routine diagnostics.","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141771626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 Infections","authors":"Medha Somisetty ,&nbsp;Philip C. Mack ,&nbsp;Chih-Yuan Hsu ,&nbsp;Yuanhui Huang ,&nbsp;Jorge E. Gomez ,&nbsp;Ananda M. Rodilla ,&nbsp;Jazz Cagan ,&nbsp;Sooyun C. Tavolacci ,&nbsp;Juan Manuel Carreño ,&nbsp;Rachel Brody ,&nbsp;Amy C. Moore ,&nbsp;Jennifer C. King ,&nbsp;Nicholas C. Rohs ,&nbsp;Christian Rolfo ,&nbsp;Paul A. Bunn ,&nbsp;John D. Minna ,&nbsp;Sheena Bhalla ,&nbsp;Florian Krammer ,&nbsp;Adolfo García-Sastre ,&nbsp;Jane C. Figueiredo ,&nbsp;David E. Gerber","doi":"10.1016/j.cllc.2024.07.007","DOIUrl":"10.1016/j.cllc.2024.07.007","url":null,"abstract":"<div><h3>Introduction</h3><div>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be spread by individuals unaware they are infected. Such dissemination has heightened ramifications in cancer patients, who may need to visit healthcare facilities frequently, be exposed to immune-compromising therapies, and face greater morbidity from coronavirus disease 2019 (COVID-19). We determined characteristics of (1) asymptomatic, clinically diagnosed, and (2) serologically documented but clinically undiagnosed SARS-CoV-2 infection among individuals with lung cancer.</div></div><div><h3>Patients and methods</h3><div>In a multicenter registry, individuals with lung cancer (regardless of prior SARS-CoV-2 vaccination or documented infection) underwent collection of clinical data and serial blood samples, which were tested for antinucleocapsid protein antibody (anti-N Ab) or IgG (N) levels. We used multivariable logistic regression models to investigate clinical characteristics associated with the presence or absence of symptoms and the presence or absence of a clinical diagnosis among patients with their first SARS-CoV-2 infection.</div></div><div><h3>Results</h3><div>Among patients with serologic evidence or clinically documented SARS-CoV-2 infection, 80/142 (56%) had no reported symptoms at their first infection, and 61/149 (40%) were never diagnosed. Asymptomatic infection was more common among older individuals and earlier-stage lung cancer. In multivariable analysis, non-white individuals with SARS-CoV-2 serologic positivity were 70% less likely ever to be clinically diagnosed (<em>P</em> = .002).</div></div><div><h3>Conclusions</h3><div>In a multicenter lung cancer population, a substantial proportion of SARS-CoV-2 infections had no associated symptoms or were never clinically diagnosed. Because such cases appear to occur more frequently in populations that may face greater COVID-19-associated morbidity, measures to limit disease spread and severity remain critical.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141839689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prehabilitation for Older Adults Undergoing Lung Cancer Surgery: A Literature Review and Needs Assessment","authors":"Jane Y. Zhao ,&nbsp;Carolyn Presley ,&nbsp;M. Lucia Madariaga ,&nbsp;Mark Ferguson ,&nbsp;Robert E. Merritt ,&nbsp;Peter J. Kneuertz","doi":"10.1016/j.cllc.2024.07.004","DOIUrl":"10.1016/j.cllc.2024.07.004","url":null,"abstract":"<div><div>Early-stage lung cancer patients are increasingly considered for preoperative systemic therapy. Older adults in particular are among the most vulnerable patients, with little known on how preoperative therapies affect the risk-benefit of surgery. We sought to summarize the current literature and elucidate existing evidence gaps on the effects of prehabilitation interventions relative to age-related functional impairments and the unique needs of older patients undergoing lung cancer surgery. A literature review was performed using PubMed and Google Scholar databases, of all scientific articles published through April 2022 which report on the effects of prehabilitation on patients undergoing lung cancer surgery. We extracted current prehabilitation protocols and their impact on physical functioning, resilience, and patient-reported outcomes of older patients. Emerging evidence suggests that prehabilitation may enhance functional capacity and minimize the untoward effects of surgery for patients following lung resection similar to, or potentially even better than, traditional postoperative rehabilitation. The impact of preoperative interventions on surgical risk due to frailty remains ill-defined. Most studies evaluating prehabilitation include older patients, but few studies report on activities of daily living, self-care, mobility activities, and psychological resilience in older individuals. Preliminary data suggest the feasibility of physical therapy and resilience interventions in older individuals concurrent with systemic therapy. Future research is needed to determine best prehabilitation strategies for older lung cancer patients aimed to optimize age-related impairments and minimize surgical risk.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141699511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osimertinib-Related QTc Prolongation: Real-World Incidence and Impact of Drug Dosing on Recurrence Risk","authors":"Olivia H. Chen, Wesley K.Y. Wong, Kevin K.S. Mok, Landon L. Chan, Candy Tang, Molly S.C. Li","doi":"10.1016/j.cllc.2024.06.012","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.06.012","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141771724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}